A National Investigators' Meeting for the "Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Study of IMM0306 for Injection (Amulirafusp Alfa) in Combination with Lenalidomide versus Placebo in Combination with Lenalidomide in Subjects with Relapsed/Refractory Follicular Lymphoma," sponsored by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco"), was successfully held in Harbin.

This milestone marks a critical step in the formulation optimization of the IMM2510 program, promising a superior treatment option for patients with advanced solid tumors through a more convenient and safer route of administration.

This milestone represents a solid step forward in the clinical development of IMC-003, laying a crucial foundation for evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics under multiple dosing regimens, and holding promise to bring new hope to patients suffering from PAH.

This pivotal trial, evaluating amulirafusp alfa in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma (R/R FL), marks the official entry of the therapy into the pivotal clinical stage.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Announces That the Phase III Study of timdarpacept (IMM01) for CMML Has Completed Enrollment of 133 Subjects, Achieving the Milestone of 132 Subjects for Interim Analysis